1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics
Metabolomics allows exploration of novel biomarkers and provides insights on metabolic pathways associated with disease. To date, metabolomics studies on CKD have been largely limited to Caucasian populations and have mostly examined surrogate end points.
In this study, we evaluated the role of metabolites in predicting a primary outcome defined as dialysis need, doubling of serum creatinine or death in Brazilian macroalbuminuric DKD patients.
Non-targeted metabolomics was performed on plasma from 56 DKD patients. Technical triplicates were done. Metabolites were identified using Agilent Fiehn GC/MS Metabolomics and NIST libraries (Agilent MassHunter Work-station Quantitative Analysis, version B.06.00). After data cleaning, 186 metabolites were left for analyses.
During a median follow-up time of 2.5 years, the PO occurred in 17 patients (30.3%). In non-parametric testing, 13 metabolites were associated with the PO. In univariate Cox regression, only 1,5-anhydroglucitol (HR 0.10; 95% CI 0.01–0.63, p = .01), norvaline and l-aspartic acid were associated with the PO. After adjustment for baseline renal function, 1,5-anhydroglucitol (HR 0.10; 95% CI 0.02–0.63, p = .01), norvaline (HR 0.01; 95% CI 0.001–0.4, p = .01) and aspartic acid (HR 0.12; 95% CI 0.02–0.64, p = .01) remained significantly and inversely associated with the PO.
Our results show that lower levels of 1,5-anhydroglucitol, norvaline and l-aspartic acid are associated with progression of macroalbuminuric DKD. While norvaline and l-aspartic acid point to interesting metabolic pathways, 1,5-anhydroglucitol is of particular interest since it has been previously shown to be associated with incident CKD. This inverse biomarker of hyperglycemia should be further explored as a new tool in DKD.
KeywordsDiabetic kidney disease Metabolomics 1,5-Anhydroglucitol
FAPESP, Sao Paulo, Brazil.
Compliance with ethical standards
Conflict of interest
Ravi I. Thadhani is a consultant to Fresenius Medical Care North America. Gesiane Tavares, Gabriela Venturini, Kallyandra Padilha, Roberto Zatz, Alexandre C. Pereira, Eugene P. Rhee, Silvia M. O. Titan declares that they have no conflict of interest.
The protocol was approved by the local Ethics Committees: the Universitary Hospital Ethics Committee (CEP-HU, Sao Paulo University) and the Ethics Committee for Analysis of Research Projects (CAPPesq, Hospital das Clínicas, Sao Paulo University).
Written informed consent was obtained from all participants and all research was performed in accordance with the 2013 Helsinki Declaration principles.
- Dungan, K. M., Buse, J. B., Largay, J., Kelly, M. M., Button, E. A., Kato, S., et al. (2006). 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care, 29(6), 1214–1219.CrossRefPubMedGoogle Scholar
- El Assar, M., Angulo, J., Santos-Ruiz, M., Ruiz de Adana, J. C., Pindado, M. L., Sánchez-Ferrer, A., et al. (2016). Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute to endothelial dysfunction related to insulin resistance in rats and morbidly obese humans. Journal of Physiology, 594(11), 3045–3060.CrossRefPubMedPubMedCentralGoogle Scholar
- Kim, W. J., Park, C. Y., Lee, K. B., Park, S. E., Rhee, E. J., Lee, W. Y., et al. (2012). Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care, 35(2), 281–286.CrossRefPubMedPubMedCentralGoogle Scholar
- Kövamees, O., Shemyakin, A., Checa, A., Wheelock, C. E., Lundberg, J. O., Östenson, C. G., et al. (2016a). Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism 11, jc20162007.Google Scholar
- Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F. 3rd, Feldman, H. I., et al. (2009). A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150(9), 604–612. (Erratum in: Ann Intern Med. 2011 Sep 20;155(6):408).CrossRefPubMedPubMedCentralGoogle Scholar
- Mika, A., Wojtowicz, W., Ząbek, A., Młynarz, P., Chmielewski, M., Sledzinski, T., et al. (2018). Application of nuclear magnetic resonance spectroscopy for the detection of metabolic disorders in patients with moderate kidney insufficiency. Journal of Pharmaceutical and Biomedical Analysis, 149, 1–8.CrossRefPubMedGoogle Scholar
- Ming, X. F., Barandier, C., Viswambharan, H., Kwak, B. R., Mach, F., Mazzolai, L., et al. (2004). Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: Implications for atherosclerotic endothelial dysfunction. Circulation, 110(24), 3708–3714.CrossRefPubMedGoogle Scholar
- Nkuipou-Kenfack, E., Duranton, F., Gayrard, N., Argilés, À, Lundin, U., Weinberger, K. M., et al. (2014). Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS ONE, 9(5), e96955.CrossRefPubMedPubMedCentralGoogle Scholar
- Rhee, E. P., Clish, C. B., Wenger, J., Roy, J., Elmariah, S., Pierce, K. A., et al. (2016). Metabolomics of chronic kidney disease progression: A case-control analysis in the chronic renal insufficiency cohort study. American Journal of Nephrology, 43(5), 366–374.CrossRefPubMedPubMedCentralGoogle Scholar
- Tazawa, S., Yamato, T., Fujikura, H., Hiratochi, M., Itoh, F., Tomae, M., et al. (2005). SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sciences, 76(9), 1039–1050. (Erratum in: Life Sci. 2010 Oct 9;87(15–16):514).CrossRefPubMedGoogle Scholar
- Titan, S. M., Vieira, J. M. Jr., Dominguez, W. V., Barros, R. T., & Zatz, R. (2011). ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: A double-blind randomized clinical trial. Clinical Nephrology, 76(4), 273–283.CrossRefPubMedGoogle Scholar